Join
Live feed
·
PRReleasevia Quantisnow
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma

ByQuantisnow·Wall Street's wire, on your screen.
VRCA· Verrica Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track VRCA (Verrica Pharmaceuticals Inc.) and more on Quantisnow.